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Endocannabinoids are lipid signaling molecules that
regulate a wide range of mammalian behaviors,
includingpain, inflammation,andcognitive/emotional
state. The endocannabinoid anandamide is princi-
pally degraded by the integral membrane enzyme
fatty acid amide hydrolase (FAAH), and there is
currently much interest in developing FAAH inhibitors
to augment endocannabinoid signaling in vivo. Here,
we report the discovery and detailed characterization
of a highly efficacious and selective FAAH inhibitor,
PF-3845. Mechanistic and structural studies confirm
that PF-3845 is a covalent inhibitor that carbamylates
FAAH’s serine nucleophile. PF-3845 selectively
inhibits FAAH in vivo, as determinedbyactivity-based
protein profiling; raises brain anandamide levels for
up to 24 hr; and produces significant cannabinoid
receptor-dependent reductions in inflammatory
pain.Thesedata thusdesignatePF-3845asavaluable
pharmacological tool for in vivo characterization of
the endocannabinoid system.
INTRODUCTION
The endogenous cannabinoid (endocannabinoid) system is
composed of two G protein-coupled receptors, CB1 and CB2;
their cognate lipid ligands N-arachidonoyl ethanolamine (anan-
damide [AEA]) and 2-arachidonoylglycerol (2-AG); and the meta-
bolic enzymes responsible for AEA and 2-AG biosynthesis and
degradation (Fowler, 2006; Pacher et al., 2006; Di Marzo et al.,
2007; Ahn et al., 2008). CB1 and CB2 are also activated by
D9-tetrahydrocannabinol (THC), the psychoactive substance
in marijuana (Mechoulam, 1986). THC and other direct CB1
agonists have long been recognized to possess medicinally
beneficial properties, such as pain relief; however, these agentsChemistry & Biology 16,also produce myriad side effects, including impairments in
cognition and motor control, that limit their broad clinical utility.
In contrast, inhibitors of the principal AEA-degrading enzyme
fatty acid amide hydrolase (FAAH) (Cravatt et al., 1996; McKin-
ney and Cravatt, 2005) and FAAH(/) mice have been found
to display analgesia (Cravatt et al., 2001; Kathuria et al., 2003;
Lichtman et al., 2004a, 2004b; Chang et al., 2006; Russo et al.,
2007), anti-inflammation (Cravatt et al., 2004; Massa et al., 2004;
Holt et al., 2005), anxiolysis (Kathuria et al., 2003; Naidu et al.,
2007; Moreira et al., 2008), and antidepression (Gobbi et al.,
2005; Naidu et al., 2007) without disruptions in motility, cogni-
tion, or body temperature (Boger et al., 2000; Cravatt et al.,
2001; Kathuria et al., 2003; Lichtman et al., 2004a). These initial
findings suggest that FAAH/AEA signaling pathways regulate
a discrete subset of the behavioral processes affected by direct
CB1 agonists. The selective pharmacological blockade of FAAH
has, therefore, emerged as an exciting strategy by which to
discern the endogenous functions of AEA-mediated endocan-
nabinoid pathways and gauge their therapeutic potential.
Several classes of FAAH inhibitors have been reported,
including reversibly (e.g., a-ketoheterocycles [Boger et al.,
2000; Leung et al., 2003; Lichtman et al., 2004a]; trifluoromethyl
ketones [Koutek et al., 1994; Boger et al., 1999; Leung et al.,
2003]) and irreversibly (e.g., carbamates [Kathuria et al., 2003];
fluorophosphonates [Deutsch et al., 1997]) acting agents. These
inhibitors each possess distinct sets of attributes and defi-
ciencies that reflect some of the most challenging aspects of
FAAH inhibitor development. Reversible inhibitors, such as the
a-ketoheterocycle OL-135, have been found to display excellent
selectivity for FAAH relative to other serine hydrolases in
mammalian proteomes, but they produce only transient eleva-
tions in AEA in vivo (Lichtman et al., 2004a). The submaximal
efficacy of reversible FAAH inhibitors may be due to their rapid
metabolism, as well as to the fact that a near-complete (>85%)
blockade of FAAH activity is required to maintain elevated AEA
levels in vivo (Fegley et al., 2005). Another challenge with devel-
oping reversible inhibitors is that inhibition of FAAH leads to
elevated levels of several N-acyl ethanolamine (NAE) substrates,411–420, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 411
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A Highly Efficacious and Selective FAAH InhibitorTable 1. Potency, Defined by kinact/Ki Values, Comparison of FAAH Inhibitors PF-3845, PF-750, and URB597
Inhibitor kinact (s
1) Ki (mM) kinact/Ki (M
1s1)
PF-3845, 10




0.0033 ± 0.0003 2.0 ± 0.3 1,590
The kinact and Ki values were obtained as described in Supplemental Experimental Procedures. Values are averages ± SD of three independent exper-
iments.
aMileni et al. (2008).which can diminish the efficiency and potency of the inhibitor
by mass-action competition with the substrate (Swinney,
2004). Irreversible inhibitors, such as the carbamate URB597
(Kathuria et al., 2003), produce a more complete blockade of
FAAH in vivo, but they also inhibit other serine hydrolases in
peripheral tissues, including several carboxylesterases (Licht-
man et al., 2004a; Alexander and Cravatt, 2005; Zhang et al.,
2007). Considering that FAAH is a serine hydrolase (Patricelli
et al., 1999) and that there are > 200 members of this enzyme
class in the human proteome, inhibitor selectivity represents a
major challenge.
Toward the goal of developing FAAH inhibitors that display
optimal efficacy and selectivity, we recently reported a class of
piperidine/piperazine ureas that inhibit FAAH with high
specificity (Ahn et al., 2007). Here, we report a detailed mecha-
nistic, structural, and pharmacological characterization of the
FAAH piperidine urea inhibitor PF-3845. Our data indicate that
PF-3845 displays an unprecedented combination of in vivo
activity and selectivity, designating this agent as a valuable phar-
macological tool for studying FAAH-regulated endocannabinoid
pathways.
RESULTS AND DISCUSSION
Optimization of Potency of Piperidine/Piperazine Urea
FAAH Inhibitors
Recently, we (Ahn et al., 2007) and others (Keith et al., 2008) have
described a class of FAAH inhibitors that contain a piperidine/
piperazine urea moiety. These agents were found to inhibit
FAAH by a covalent, irreversible mechanism involving the carba-
mylation of FAAH’s catalytic S241 nucleophile. Lead urea inhib-
itors, such as PF-750 (Table 1), however, showed only moderate
potency for FAAH, as determined by measurements of kinact/Ki
values (800 M1s1). In an effort to improve the potency of
piperidine/piperazine urea inhibitors, we explored a series of412 Chemistry & Biology 16, 411–420, April 24, 2009 ª2009 Elsevieranalogs in which the quinoline group of PF-750 was replaced
by a biaryl ether group (Table 2). This medicinal chemistry effort
culminated in the discovery of PF-3845 (compound 10, Table 2),
a biaryl ether piperidine that displayed a 10- to 20-fold higher
kinact/Ki value for FAAH compared to PF-750 or the well-studied
carbamate FAAH inhibitor URB597 (Kathuria et al., 2003) (Tables
1 and 2). Key features of PF-3845 that contribute to enhanced
potency include the p-trifluoromethyl substituent on the biaryl
ether moiety and substitution of the aniline leaving group of
PF-750 with 3-aminopyridine.
We next examined the mechanism of FAAH inhibition by
PF-3845 in more detail by using an enzyme-coupled assay
with oleamide as a substrate, where stoichiometric quantities
of NAD+ are formed upon the generation of ammonia from
oleamide by FAAH hydrolysis (Ahn et al., 2007). Linear produc-
tion of NAD+ was observed over a 40 min time period in the
absence of PF-3845 (see Figure S1A available online). In the
presence of PF-3845, the progress curves for oleamide hydro-
lysis by FAAH exhibited curvature (Figure S1A), consistent with
an irreversible mechanism of inhibition. The data were fit to a
pseudo-first-order decay equation to determine kobs values at
each inhibitor concentration. Plotting these kobs values as a func-
tion of PF-3845 concentration revealed saturation (Figure S1B),
thus supporting a two-step mechanism for FAAH inactivation
involving reversible binding of PF-3845 to FAAH, followed by
the second chemical step that results in covalent bond forma-
tion. Based on this model, kinact and Ki values for FAAH inhibition
by PF-3845 were calculated to be 0.0033 ± 0.0002 s1 and
0.23 ± 0.03 mM, respectively (Table 1). Similar progress and satu-
ration curves were plotted for inhibition of FAAH by the carba-
mate inhibitor URB597 (Figures S1C and S1D), generating kinact
and Ki values of 0.0033 ± 0.0003 s
1 and 2.0 ± 0.3 mM, respec-
tively (Table 1). These data thus indicate that most, if not all, of
the increased potency observed for PF-3845 over URB597 is
due to an improvement in binding affinity (Ki value).Ltd All rights reserved
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A Highly Efficacious and Selective FAAH InhibitorTable 2. Structure-Activity Relationship of Biaryl Ether Urea FAAH Inhibitors
kinact/Ki (M
1s1)
Compound R Y X hFAAH rFAAH h/rFAAH
1 4-MePh C N 1440 ± 260 303 ± 41 974 ± 490
2 4-OMePh C N 1370 ± 300 1190 ± 600 1600 ± 340
3 4-CF3Ph C N 4070 ± 22 1340 ± 370 -
4 4-CF3-2-pyr C N 4160 ± 570 1520 ± 220 -
5 Ph C C 1280 ± 390 314 ± 55 -
6 4-MePh C C 4640 ± 170 531 ± 37 -
7 4-CF3Ph C C 9230 3600 2140 ± 660 -
8 4-FPh C C 3460 ± 390 445 ± 110 2470 ± 130
9 2-pyr C C 1090 ± 340 76 ± 1 -
10 (PF-3845) 4-CF3-2-pyr C C 12,600 ± 3,000 3900 ± 780 13,300 ± 1,300
11 3-CF3-2-pyr C C 267 ± 51 86 ± 7 -
12 6-CF3-2-pyr C C 438 ± 260 69 ± 25 -
13 4-OMe-2-pyr C C 4780 ± 390 2850 ± 170 -
14 4-NH2-2-pyr C C 368 ± 140 64 ± 3 -
15 4-MePh N N 17 ± 1 11 ± 3 -
Values are averages ± SD of two independent experiments.Crystal Structure of a PF-3845-FAAH Complex
To gain more detailed insights into the basis for the improved
potency of PF-3845, we next determined the crystal structure
of a PF-3845-FAAH complex. Here, we used a recently
described ‘‘humanized’’ rat-FAAH (h/rFAAH) protein, in which
the active site of rat FAAH (rFAAH) has been mutagenically con-
verted to match the active site of human FAAH (hFAAH) (Mileni
et al., 2008). Previous studies have confirmed that h/rFAAH
maintains the high recombinant expression levels of rFAAH
and the inhibitor sensitivity profile of hFAAH (Mileni et al.,
2008), thus providing a versatile model for structure-activity rela-
tionship (SAR) studies relevant to the human enzyme.
A crystal structure of the PF-3845-h/rFAAH complex was
determined at 2.8 A˚ resolution (see Table S1 for data collection
and refinement statistics), revealing a dimeric enzyme with an
overall fold that matched those reported in previous FAAH struc-
tures (Bracey et al., 2002; Mileni et al., 2008). PF-3845 was found
to be covalently attached to the catalytic S241 nucleophile
(Patricelli et al., 1999) of h/rFAAH through a carbamate linkage
(Figure 1), similar to the previously reported structure of h/rFAAH
complexed with PF-750 (Mileni et al., 2008). The 3-aminopyri-
dine leaving group was not observed in the h/rFAAH structure,
but the remaining piperidine portion of the parentmolecule occu-
pied the acyl chain-binding pocket (Figure 1A). As was observed
in the PF-750-h/rFAAH structure (Mileni et al., 2008), a strong
aromatic C-H.p interaction (Brandl et al., 2001) can be seen
between F192 and the phenyl aromatic ring of PF-3845
(Figure 1A). The 20-fold improvement in potency for PF-3845
appears to derive from a more extended set of van der WaalsChemistry & Biology 16,interactions between this inhibitor’s 4-trifluoromethyl-2-pyridyl
group and the hydrophobic acyl chain-binding pocket of FAAH
(Figure 1B). In this respect, the biaryl ether piperidine moiety of
PF-3845 binds in a fashion that more closely resembles the
arachidonyl chain of the original methyl arachidonyl phospho-
nate (MAP)-rFAAH crystal structure (Bracey et al., 2002)
(Figure 1C).
One marked difference that we previously observed between
the crystal structures of FAAH bound to MAP (Bracey et al.,
2002) and PF-750 (Mileni et al., 2008) was that the shorter
PF-750 group allowed F432 to undergo a conformational shift
that moved this residue out of the membrane access channel
and into the acyl chain-binding pocket (Figure 1B). In the
PF-3845-h/rFAAH structure, F432 resides in the membrane
access channel at a site similar to its position in the MAP-rFAAH
structure (Figure 1C). Adjacent to F432, residue M436 also
undergoes a rotation of about 135 along the Ca-Cb axis in
both the PF-3845 and MAP-FAAH structures (Figure 1C). The
structural rearrangements of F432 and M436 thus appear to
occur in a coordinated manner in these three structures and
establish that inhibitors can promote conformational shifts that
alter the relative size of FAAH’s acyl chain-binding pocket and
membrane access channel. The dynamic nature of this region
of FAAH could facilitate entrance of lipid substrates from the
cell membrane into the enzyme’s active site.
The PF-3845-FAAH structure also aided our understanding of
the SAR within the biaryl ether urea series by means of Monte
Carlo simulations and energy calculations. For example, these
calculations suggest that the higher potency of piperidine ureas411–420, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 413
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A Highly Efficacious and Selective FAAH InhibitorFigure 1. Crystal Structure of a PF-3845-h/rFAAH Complex
(A) Active site image of the PF-3845-h/rFAAH complex, showing the S241-
carbamylated adduct and six residues that have been mutated in h/rFAAH.
(B) Overlap of the crystal structures of the PF-3845 (gray) and PF-750 (green)
complexes with h/rFAAH, showing the different modes of binding that lead
to distinct conformations for the F432 residue that toggles between the
membrane access (MA) channel (F432 in gray) and the acyl chain-binding
(AB) pocket (F432 in green).
(C) Overlap of the crystal structures of PF-3845-h/rFAAH and MAP-rFAAH
complexes, showing similar bindingmodes for PF-3845 (gray) andMAP (blue).414 Chemistry & Biology 16, 411–420, April 24, 2009 ª2009 Elsevier(compounds 6, 7, 10; Table 2) over the corresponding piperazine
ureas (compounds 1, 3, 4; Table 2) is likely due to unfavorable
electrostatic interactions of the protonated piperazine within
the hydrophobic acyl chain-binding pocket. Furthermore,
replacement of the central phenyl group of PF-3845with a pyridyl
group drastically reduces inhibitor potency (compound 15;
Table 2), which may reflect disruption of the aromatic-CH.p
interaction with F192 caused by the higher electron withdrawing
character of the pyridyl nitrogen, which lessens the electron
density of the p ring. Finally, the crystal structure provides
an attractive model to explain the improved potency gained
by insertion of a trifluoromethyl group at the 4 position of the
2-pyridyl ring that resides in the acyl chain-binding pocket.
Reducing the size of this substituent to a methyl or fluoro group
decreased inhibitor potency (compounds 6 and 8, respectively;
Table 2), which can be rationalized by simulations that predict
suboptimal van der Waals contacts for these smaller groups.
Conversely, moving the trifluoromethyl group to the 3 or 6 posi-
tion, which also impairs potency (compounds 11 and 12, respec-
tively; Table 2), is predicted to introduce steric clashes with the
FAAH protein.
PF-3845 Selectively Inhibits FAAH In Vivo for up to 24 hr
We next administered PF-3845 to mice (10 mg/kg, i.p.) and
monitored FAAH inactivation and substrate levels in the brain
over a time course from 1 to 24 hr. For comparison, we also
analyzed mice treated with URB597 (10 mg/kg, i.p.). Both
PF-3845- and URB597-treated mice showed rapid and
complete inactivation of FAAH in the brain, as judged by compet-
itive activity-based protein profiling (ABPP) (Liu et al., 1999;
Leung et al., 2003) with the serine hydrolase-directed probe
fluorophosphonate (FP)-rhodamine (Patricelli et al., 2001)
(Figure 2A). PF-3845 showed a longer duration of action than
URB597, as judged by the rate of recovery of FP labeling of
FAAH. Whereas URB597-treated animals showed nearly wild-
type levels of brain FAAH activity by 24 hr, FAAH was still mostly
inhibited (>75%) at this time point in PF-3845-treated animals
(Figure 2A). These ABPP studies confirmed that PF-3845 and
URB597 were both highly selective for FAAH in the brain, since
none of the other FP-reactive serine hydrolases in this tissue
were inhibited by these agents. In contrast, URB597, but not
PF-3845, blocked FP labeling of several additional liver serine
hydrolases (Figure 2B), which have previously been identified
as carboxylesterases (Alexander and Cravatt, 2005; Zhang
et al., 2007). We furthermore tested PF-3845 for the effects on
FAAH-2, a recently identified FAAH homolog that is selectively
expressed in higher mammals (Wei et al., 2006), but not rodents.
In contrast to URB597, which has been found to inhibit human
FAAH-2 with high potency (Wei et al., 2006), PF-3845 showed
negligible activity against this FAAH variant (IC50 > 10 mM;
Figure S2).
To confirm the in vivo selectivity of PF-3845, we synthesized
an alkyne analog of this inhibitor, termed PF3845yne
(Figure 3A), which maintained high potency for FAAH (kinact/Ki
value of 5230 M1s1). We then directly analyzed the protein
targets of PF3845yne in vivo by click chemistry (CC)-ABPP
(Speers et al., 2003; Speers and Cravatt, 2004; Alexander and
Cravatt, 2005). For these studies, we compared the labeling
profile of PF3845yne to those of JP104 (Figure 3B), a previouslyLtd All rights reserved
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A Highly Efficacious and Selective FAAH InhibitorFigure 2. In Vivo Selectivity Analysis for PF-3845 and URB597 as
Determined by Competitive ABPP
(A) Gel profiles of FP-rhodamine-labeled brain serine hydrolase activities from
mice treated with PF-3845 or URB597 (10 mg/kg, i.p.) for the indicated times.
Note that selective blockade of FP-rhodamine labeling of FAAH is observed by
both inhibitors. Representative additional brain serine hydrolases are desig-
nated based on previous ABPP studies (Blankman et al., 2007; Nomura
et al., 2008).
(B) Gel profiles of FP-rhodamine-labeled liver serine hydrolase activities from
mice treated with PF-3845 or URB597 (10 mg/kg, i.p., 2 hr). Note that
URB597, but not PF-3845, blocks FP-rhodamine labeling of several liver serine
hydrolase activities (bracket), which have previously been identified as carbox-
ylesterases (Alexander and Cravatt, 2005; Zhang et al., 2007). For both (A) and
(B), fluorescent gel images are shown in grayscale. For (B), a lower scanning
intensity is shown due to the highly abundant activity signals for carboxyles-
terases present in the liver proteome.described alkyne analog of URB597 (Alexander and Cravatt,
2005). PF3845yne and JP104 were administered to FAAH(+/+)
and (/) mice (10 mg/kg, i.p.), and, after 2 hr, animals were
sacrificed and their brain and liver proteomes analyzed by
CC-ABPP by using an azide-rhodamine tag. Consistent with
the results of our competitive ABPP experiments (Figure 2),
PF3845yne and JP104 selectively reacted with a single protein
in mouse brain that was confirmed as FAAH based on its
absence in FAAH(/) mice (Figure 3C). In liver, however,
PF3845yne and JP104 showed strikingly different profiles, withChemistry & Biology 16the former agent once again showing selective reactivity with
FAAH and the latter inhibitor labeling a number of proteins that
were found in both FAAH(+/+) and (/) mice (Figure 3D). A
single faint 60 kDa labeling event was observed in liver pro-
teomes from PF3845yne-treated FAAH(/) mice, but a similar
signal was also detected in vehicle-treated animals, suggesting
that this protein may represent a nonspecific target of the
azide-rhodamine tag. Collectively, these data indicate that
PF-3845 inhibits FAAH in vivo with exceptional efficacy and
selectivity.
FAAH Inhibition by PF-3845 Causes a Dramatic
and Sustained Elevation in AEA
Previous studies with FAAH(/) mice (Cravatt et al., 2001;
Saghatelian et al., 2004) and rodents treated with FAAH inhibi-
tors (Kathuria et al., 2003; Saghatelian et al., 2004) have
confirmed a key role for FAAH in regulating tissue levels of
AEA and other NAEs. We found that PF-3845-treated mice
(10 mg/kg, i.p.) also showed dramatic (>10-fold) elevations in
brain levels of AEA (Figure 4A) and other NAEs (N-pamitoyl etha-
nolamine [PEA] [Figure 4B] and N-oleoyl ethanolamine [OEA]
[Figure 4C]). These animals also showed significant elevations
in AEA, PEA, and OEA levels in liver tissue (Figures S3A). In
contrast, PF-3845-treated animals did not show changes in the
levels of 2-AG in brain or liver (Figure S3B), consistent with
previous findings indicating that distinct enzymes regulate this
endocannabinoid in vivo (Kathuria et al., 2003; Blankman et al.,
2007; Long et al., 2009). We also confirmed that PF-3845 did
not alter endocannabinoid (AEA or 2-AG) levels in FAAH(/)
mice (Figure S3C).
PF-3845-induced elevations in NAEs peaked at 3 hr and
were maintained at maximal levels for up to 7–12 hr, after which
they slowly declined. This decline was faster for AEA than for
PEA or OEA, possibly reflecting that AEA is a much preferred
substrate for FAAH (Cravatt et al., 1996; Wei et al., 2006) and
therefore more sensitive to low levels of enzyme recovery. The
slightly faster rate of recovery for OEA versus PEA is alsoFigure 3. Direct Analysis of In Vivo Protein
Targets of Alkyne Analogs of PF-3845 and
URB597 by CC-ABPP
(A) Structure of PF3845yne, an alkyne analog of
PF-3845.
(B) Structure of JP104, an alkyne analog of
URB597 (Alexander and Cravatt, 2005).
(C and D) Gel profiles of CC-ABPP experiments in
which (C) brain or (D) liver proteomes from
PF3845yne- and JP104-treated mice (10 mg/kg,
i.p., 2 hr) were treated with a rhodamine-azide
tag under CC conditions and analyzed by in-gel
fluorescence scanning (shown in grayscale).
PF3845yne selectively labels FAAH in both brain
and liver tissue (60 kDa band absent in FAAH(/)
mice), whereas JP104 labels several additional
proteins in liver (protein bands present in both
FAAH(+/+) and (/) mice). Note that the 55 kDa
protein band observed in liver proteome from
PF-3845-treated FAAH(/) mice was also de-
tected in liver proteomes from vehicle-treated
FAAH(+/+) and (/) mice and therefore likely
represents a background protein that is cross-
reactive with the azide-rhodamine tag., 411–420, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 415
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A Highly Efficacious and Selective FAAH InhibitorFigure 4. Brain Levels of FAAH Substrates and Inhibitors
(A–C) Brain levels of (A) AEA, (B) PEA, and (C) OEA measured at the indicated time points after treatment with PF-3845 or URB597 (10 mg/kg, i.p.). *p < 0.05;
**p < 0.01 for inhibitor-versus-vehicle-treated groups. n = 4 mice/group.
(D) Brain levels of PF-3845 and URB597 measured at the indicated time points after inhibitor treatment.consistent with the relative activity that FAAH displays for these
substrates in vitro (Wei et al., 2006). Despite FAAH’s preference
for hydrolyzing AEA, significant elevations in this NAE (as well as
PEA and OEA) were still observed at 24 hr posttreatment with
PF-3845, consistent with the substantial level of FAAH inhibition
maintained at this time point (Figure 2A). URB597-treated mice
also showed elevations in NAEs, but these increases were
more transient, with AEA levels returning to near-baseline levels
by 7 hr posttreatment (Figures 4A–4C). The different rates of
recovery of both FAAH activity (Figure 2A) and NAE levels
(Figures 4A–4C) in mice treated with PF-3845 versus URB597
likely reflect the distinct half-lives of these inhibitors in vivo, since
higher relative brain levels of PF-3845 were maintained over the
time course analysis (Figure 4D).
PF-3845 Produces Cannabinoid Receptor-Dependent
Reductions in Inflammatory Pain
We next assessed whether PF-3845 was efficacious in a rat
model of inflammatory pain. Subcutaneous injection of complete
Freund’s adjuvant (CFA) into the plantar surface of the hind paw
produced a significant decrease in mechanical paw weight
threshold (PWT) at 5 days postinjection (Figure 5A). PF-3845
(1–30 mg/kg, oral administration [p.o.]) caused a dose-
dependent inhibition of mechanical allodynia with a minimum
effective dose (MED) of 3 mg/kg (rats were analyzed at 4 hr post-
dosing with PF-3845). At higher doses (10 and 30 mg/kg),
PF-3845 inhibited pain responses to an equivalent, if not greater,
degree than the nonsteroidal anti-inflammatory drug naproxen
(10mg/kg, p.o.) (Figure 5A). We next determined the relationship
between the in vivo efficacy andmodulation of FAAH activity and
substrates (i.e., NAEs) by PF-3845 in central (brain) and periph-
eral systems (peripheral blood leukocytes/plasma, liver). Robust,
near-complete inhibition of FAAH activity (Figure 5B; Figure S4A)
with concomitant elevations in AEA (Figure 5C) and other NAEs
(Figures S4B, S4C, and S5) were observed in brain, peripheral
blood leukocytes/plasma, and liver from PF-3845-treated
animals. Interestingly, we observed a slightly left-shifted dose-
response profile for measurements of FAAH activity and NAEs
compared to efficacy in the CFAmodel. For instance, at 1mg/kg,
PF-3845 was found to produce a near-complete blockade of
FAAH activity (Figure 5B) and close to maximal elevations in
AEA (Figure 5C), but efficacy was not observed at this dose of
inhibitor (Figure 5A). These data may indicate the need to fully
block FAAH (and fully elevate AEA levels) in order to observe416 Chemistry & Biology 16, 411–420, April 24, 2009 ª2009 Elsevierantiallodynic effects in the CFA model. Alternatively, the kinetics
of FAAH blockade may have been slower at lower doses of
PF-3845, which could reduce efficacy in painmodels that require
sustained elevations in AEA. It is also noteworthy that the
maximal elevations observed for AEA in PF-3845-treated
animals were similar in brain and plasma (10-fold), whereas
OEA and PEA were increased to a lower extent in plasma
(3-fold) compared to brain (10-fold). This might suggest the
existence of alternative degradative (Tsuboi et al., 2005) (or
biosynthetic [Leung et al., 2006]) pathways for AEA versus
OEA/PEA in peripheral tissues.
Considering that mice treated with PF-3845 showed high
(>10-fold) elevations in AEA that lasted for at least 7 hr, we
next evaluated the duration of action of this inhibitor in the CFA
model from 2–8 hr postadministration. PF-3845 (10 mg/kg,
p.o.) exhibited significant inhibition of mechanical allodynia at
all time points tested (Figure 5D), although this effect appeared
to diminish in magnitude by 8 hr. This loss in activity could reflect
gradual recovery of FAAH activity in PF-3845-treated rats, as
may be reflected in the decline in AEA levels that was observed
at a similar time point in mice treated with this inhibitor (see Fig-
ure 4A). However, further time course studies in rats will be
required to accurately estimate the duration of action of
PF-3845 in these animals. We next examined the involvement
of cannabinoid receptors in the PF-3845-induced antiallodynia.
Specific antagonists for central CB1 (SR141716) and peripheral
CB2 (SR144528) receptors each partially, but significantly,
reduced the antiallodynia activity of PF-3845 (Figure 5E).
Notably, dual treatment with SR141716 and SR144528
produced a near-complete ablation of the efficacy of PF-3845
in the CFA model (Figure 5E). These data indicate that PF-3845
blocks inflammatory pain responses in the CFA model by
a cannabinoid receptor-dependent mechanism that likely
involves both CB1 and CB2 receptors, as has been shown for
other FAAH inhibitors (Jayamanne et al., 2006).
Conclusions
Endocannabinoids, like other lipid signaling molecules, are
thought to be produced on demand by neurons, rather than
being stored in synaptic vesicles like classical neurotransmitters
(Ahn et al., 2008; Di Marzo, 2008). Although protein-mediated
uptake pathways may exist for endocannabinoids (Hillard and
Jarrahian, 2003; McFarland and Barker, 2004; Glaser et al.,
2005; Fowler, 2006), the hydrophobic nature of these lipidsLtd All rights reserved
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A Highly Efficacious and Selective FAAH InhibitorFigure 5. Antihyperalgesic Effects of PF-3845 in the CFA Model of Inflammatory Pain
(A) PF-3845 produces a dose-dependent reduction of mechanical allodynia (hyperalgesia) in rats (black bars). The effect of the nonsteroidal anti-inflammatory
drug naproxen (10 mg/kg, p.o., hatched bar) is shown for comparison. Paw-withdrawal thresholds were measured 4 hr postadministration of drugs.
(B and C) PF-3845-treated rats show significant blockade of (B) FAAH activity and elevated (C) AEA levels in brain tissue and blood leukocytes/plasma. All FAAH
activity and NAE measurements were determined at 4 hr after drug treatment and were significantly different between PF-3845- and vehicle-treated groups
(p < 0.001, n = 3 rats/group).
(D) Time course for antihyperalgesic effects of PF-3845 (10 mg/kg, p.o.).
(E) Blockade of antihyperalgesic effects of PF-3845 (10 mg/kg, i.p.) by CB1 and CB2 antagonists (SR141716 and SR144528, respectively; 10 and 30 mg/kg, i.p.,
respectively, administered 1 hr prior to measurement of paw-withdrawal thresholds). Note that neither the CB1 nor the CB2 antagonist displayed significant
effects on mechanical allodynia in rats not treated with PF-3845 (hatched bars). #p < 0.001, for PF-3845- versus vehicle-treated groups. *p < 0.05; **p < 0.01;
***p < 0.001, for vehicle-PF-3845- versus CB1/CB2 antagonist-PF-3845-treated groups . n = 8 rats/group.also grants them the ability to freely diffuse across cell
membranes. This feature assigns primary responsibility for
signal termination to degradative enzymes, such as FAAH. The
pharmacological blockade of FAAH has, thus, emerged as
a strategy by which to elevate endocananbinoid signaling
in vivo and to study the behavioral consequences. Over the
past decade, several classes of FAAH inhibitors have been
described that vary in their mechanism of action, potency, selec-
tivity, and in vivo efficacy. Arguably, the most well-studied FAAH
inhibitor to date is URB597 (Kathuria et al., 2003), a carbamate
that irreversibly inhibits FAAH with high selectivity in the nervous
system (Alexander and Cravatt, 2005). However, URB597
displays some notable shortcomings, including the inactivation
of other serine hydrolases in peripheral tissues (Alexander and
Cravatt, 2005; Zhang et al., 2007) and a relatively limited duration
of action in vivo. Development of a FAAH inhibitor that displays
an optimal combination of efficacy and selectivity has, therefore,
remained an intensely pursued objective.
We have described herein the detailed characterization of an
advanced piperidine urea inhibitor of FAAH, PF-3845. Our data
argue that PF-3845 displays remarkable selectivity for FAAH
and robust efficacy in vivo, as reflected in sustained elevations
of brain AEA that correlate with cannabinoid receptor-
dependent reductions in inflammatory pain responses.Chemistry & Biology 16PF-3845 also induces elevations in other noncannabinoid
NAEs (e.g., OEA, PEA), which may have additional effects on
inflammation and other physiological processes (Lambert
et al., 2002). Structural and kinetic studies indicate that the
improved potency of PF-3845 compared to previously
described inhibitors (URB597, PF-750) likely originates from
more extended van der Waals contacts with the hydrophobic
FAAH acyl chain-binding tunnel. This premise is also supported
by SAR data generated with a set of biaryl ether analogs of
PF-3845, in which the introduction of polar groups within
certain regions of the inhibitor scaffold severely impaired
activity (e.g., compound 16, Table 2).
In summary, the properties of PF-3845 defined in this study
indicate that this agent should be considered a frontline inhibitor
for the pharmacological investigation of FAAH-regulated endo-
cannabinoid pathways. Differentiating properties of PF-3845
include its high target selectivity, extended duration of action,
and excellent oral bioavailability (>80%, data not shown). These
features should make PF-3845 particularly well suited for
studying the role of the endocannabinoid system in both central
and peripheral physiological processes, as well as chronic path-
ological syndromes (e.g., neuropathic pain, depression) that
may require sustained elevations in endocannabinoid tone for
rectification., 411–420, April 24, 2009 ª2009 Elsevier Ltd All rights reserved 417
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The endocannabinoid system regulates a number of impor-
tant physiological processes in mammals and is the prin-
cipal site of action for THC, the psychoactive ingredient in
marijuana. THC and other direct agonists of the CB1
receptor have potentially useful medicinal properties, such
as pain relief, but these activities are accompanied by
a variety of untoward side effects, including impairment in
motor control and cognitive function. In contrast, blockade
of endocannabinoid-metabolizing enzymes such as FAAH
has been shown to reduce pain sensation, inflammation,
and anxiety/depression without substantial effects on
motility or cognition. Despite considerable advances in the
development of FAAH inhibitors, agents that combine high
target selectivity with exceptional in vivo efficacy are still
needed. Here, we report the discovery and detailed charac-
terization of PF-3845, a piperidine urea FAAH inhibitor that
satisfies these criteria. PF-3845 was shown by mechanistic
and structural studies to covalently inactivate FAAH by car-
bamylation of the enzyme’s serine nucleophile. PF-3845
completely inhibited FAAH activity, but did not react with
other serine hydrolases in vivo, as determined by activity-
based proteomics; raised brain levels of the endocannabi-
noid AEA for up to 24 hr; and produced significant CB1/
CB2-dependent antihyperalgesic effects in the CFA model
of inflammatory pain. From these data, we conclude that
PF-3845 is a highly selective and efficacious inhibitor of
FAAH that should prove to be a valuable pharmacological





synthesized as described previously (Ahn et al., 2007). URB597 and JP104
were purchased from Cayman Chemicals (Ann Arbor, MI). Inhibitors were
stored as dry powders at room temperature and dissolved in DMSO to prepare
concentrated stock solutions for the in vitro potency measurements.
SR141716 and SR144528, selective CB1 and CB2 receptor antagonists,
were synthesized at Pfizer. Polystyrene 96- and 384-microplates were
purchased from Rainin and Evergreen Scientific (Los Angeles, CA), respec-
tively. All reagents used were the highest quality commercially available.
Synthesis of PF-3845 and Structural Analogs
The synthesis of PF-3845 and other biaryl ether piperidine/piperazine ureas
was performed as described in Supplemental Experimental Procedures.
FAAH Expression and Purification
All three forms of FAAH (hFAAH, rFAAH, and h/rFAAH) were expressed and
purified by following previously described procedures (Mileni et al., 2008)
and as described in Supplemental Experimental Procedures.
Determination of Inhibitor Potency
Inhibitor potencies were determined by following previously described proce-
dures (Mileni et al., 2008) and as described in Supplemental Experimental
Procedures.
h/rFAAH Crystallography
Crystallization and structure determination were performed as described in
Supplemental Experimental Procedures.418 Chemistry & Biology 16, 411–420, April 24, 2009 ª2009 ElsevierMonte Carlo Simulations of FAAH Inhibitor Adducts
The program ICM-Pro (Molsoft, L.L.C.) was used to simulate covalent docking
of biaryl ether urea inhibitors into the active site of the h/rFAAH as described in
Supplemental Experimental Procedures. As a positive control, we performed
the docking of the PF-3845 ligand, which provided a conformation that closely
matched the conformation observed in the PF-3845-FAAH crystal structure.
Competitive ABPP Studies
PF-3845 or URB597 (neat) were dissolved at 1 mg/ml by sonication and vor-
texing directly into a solution of 18:1:1 v/v/v saline:emulphor:ethanol. Male
C57Bl/6J mice (6–12 weeks old, 20–28 g) were intraperitoneally (i.p.) adminis-
tered PF-3845, URB597, or an 18:1:1 v/v/v saline:emulphor:ethanol vehicle at
a volume of 10 ml/g weight (10 mg/kg final dose). After the indicated amount of
time, mice were anesthetized with isofluorane and sacrificed by decapitation.
Brains were removed and hemisected along the midsagittal plane, and each
half was then flash frozen in liquid N2. One half of the brain was homogenized
in PBS (pH 7.4, 2 ml), diluted to 1 mg protein/ml; treated with FP-rhodamine
(1 mM, 0.5 hr); and analyzed by gel-based ABPP by following previously
described methods (Alexander and Cravatt, 2005). The other half of the brain
was used for lipid and drug measurements as detailed in Supplemental Exper-
imental Procedures.
CC-ABPP Studies
CC-ABPP studies were performed by following previously described proce-
dures (Speers et al., 2003; Speers and Cravatt, 2004; Alexander and Cravatt,
2005) and as detailed in Supplemental Experimental Procedures.
Measurement of FAAH Activity and Lipid Levels from Rat Tissues
and Blood Leukocytes
Preparation of rat tissue (brain and liver) and blood leukocytes for measuring
FAAH activity and lipid levels is described in Supplemental Experimental
Procedures.
Analysis of PF-3845 Effects in the CFA Model of Inflammatory Pain
Male Sprague-Dawley rats (200–250 g) were used for all experiments.
Rats were given free access to food and water and were maintained on a
12/12 hr light/dark cycle. For the inflammatory pain model, 0.15 ml CFA
(Sigma) was injected into the plantar surface of the left hind paw of the rat.
The CFA injection immediately induces local inflammation, paw swelling,
and pain, which persist for at least 2 weeks postinjection. To assess mechan-
ical allodynia, mechanical paw-withdrawal thresholds (PWTs) were measured
by using a set of Von Frey Hairs on day 5 postinjection as illustrated by the
DixonUp andDownMethod (Dixon, 1980). Animals that exhibit the pain criteria
of 9 g or less were then placed on study. Test compound was administered via
either oral or i.p. routes at the indicated concentrations (mg/kg) with the dosing
vehicle 5% N,N-dimethylacetamide and 95% 2-hydroxypropyl-b-cyclodextrin
(40%) (Sigma) in water). PWTs were evaluated again at 4 hr postdosing. PWT
measurements were averaged, and statistical comparisons between groups
were made by using analysis of variance and unpaired t tests. The Pfizer Insti-
tutional Animal Care and Use Committee reviewed and approved the animal
use in these studies. The animal care and use program is fully accredited by
the Association for Assessment and Accreditation of Laboratory Animal
Care, International.
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures, one
table, and five figures and can be found with this article online at http://
www.cell.com/chemistry-biology/supplemental/S1074-5521(09)00080-5.
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